Medline (NASDAQ:MDLN) Given New $49.00 Price Target at UBS Group

Key Points

• UBS raised its Medline price target to $49 from $43 and maintained a Buy rating, implying 23.24% upside from the previous close.
• Analyst sentiment is broadly positive: 23 analysts rate the stock Buy, four Hold and two Sell, for a consensus Moderate Buy rating and $46.08 average target.
• Medline reported quarterly EPS of $0.44, beating the $0.32 consensus, on $7.86 billion in revenue; the stock nevertheless fell 1.5% on Thursday.

Medline (NASDAQ:MDLN - Get Free Report) had its target price boosted by equities researchers at UBS Group from $43.00 to $49.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. UBS Group's price target would suggest a potential upside of 23.24% from the stock's previous close.

Other research analysts have also recently issued research reports about the stock. BMO Capital Markets restated an "outperform" rating and set a $47.00 price objective on shares of Medline in a report on Thursday, August 6th. JPMorgan Chase & Co. cut their target price on shares of Medline from $53.00 to $46.00 and set an "overweight" rating on the stock in a report on Wednesday, August 12th. William Blair reissued an "outperform" rating on shares of Medline in a research report on Wednesday, September 23rd. Citigroup lifted their price target on shares of Medline from $45.00 to $47.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, Zacks Research lowered shares of Medline from a "hold" rating to a "strong sell" rating in a report on Tuesday, October 20th. Twenty-three analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $46.08.

Medline Trading Down 1.5%

MDLN traded down $0.59 during midday trading on Thursday, reaching $39.76. 14,219,667 shares of the company were exchanged, compared to its average volume of 7,779,645. The stock has a market capitalization of $52.27 billion and a P/E ratio of 50.33. Medline has a one year low of $31.37 and a one year high of $50.88. The stock's 50-day simple moving average is $34.68 and its 200 day simple moving average is $39.51. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.61 and a current ratio of 4.33.

Medline (NASDAQ:MDLN - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.32 by $0.12. The company had revenue of $7.86 billion during the quarter. As a group, analysts forecast that Medline will post 1.49 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Private Ltd Gic sold 2,570,999 shares of the business's stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $35.35, for a total value of $90,884,814.65. Following the completion of the transaction, the insider directly owned 20,231,483 shares in the company, valued at approximately $715,182,924.05. The trade was a 11.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders sold 8,538,960 shares of company stock valued at $302,807,442. 0.81% of the stock is currently owned by insiders.

Institutional Trading of Medline

Several hedge funds have recently bought and sold shares of MDLN. GAMMA Investing LLC lifted its stake in Medline by 68.3% in the second quarter. GAMMA Investing LLC now owns 626 shares of the company's stock valued at $25,000 after buying an additional 254 shares in the last quarter. Whipplewood Advisors LLC bought a new stake in shares of Medline during the first quarter worth $30,000. Reyes Financial Architecture Inc. bought a new stake in shares of Medline during the third quarter worth $30,000. NewEdge Advisors LLC increased its position in shares of Medline by 100.0% during the second quarter. NewEdge Advisors LLC now owns 950 shares of the company's stock worth $37,000 after acquiring an additional 475 shares in the last quarter. Finally, Allworth Financial LP raised its holdings in shares of Medline by 86.2% during the second quarter. Allworth Financial LP now owns 1,052 shares of the company's stock worth $41,000 after acquiring an additional 487 shares during the period.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Quarterly results beat expectations. Medline reported third-quarter earnings of $0.44 per share, versus the $0.32 consensus estimate, on $7.86 billion in revenue. Reports also said the company raised its full-year growth outlook. Medline Q3 2026 earnings
• Positive Sentiment: Analyst price targets moved higher. Citigroup raised its target to $47 and assigned a Buy rating; Leerink Partners raised its target to $46 and maintained an Outperform rating. BTIG reaffirmed Buy with a $55 target, and Barclays also issued a Buy rating. The upgrades suggest analysts see further potential after the results. Citigroup rating Leerink Partners rating BTIG rating Barclays rating
• Positive Sentiment: Share repurchases provided another supportive signal. Coverage highlighted a $1 billion share-buyback program alongside the earnings beat. Medline Q3 beat and buybacks
• Neutral Sentiment: Medline plans to raise prices in 2027 to help offset inflation. The changes could support margins, though their effect on customer demand is uncertain; the company also reaffirmed its 2026 adjusted EBITDA outlook. Medline pricing plans and Q3 results
• Negative Sentiment: A law firm announced an investigation into potential securities-law violations related to alleged product-quality issues. The announcement is an overhang, although it is an investigation notice rather than a finding of wrongdoing. Medline investigation announcement

Medline Company Profile

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.